Esperion Therapeutics Inc. (ESPR) saw an uptrend of 8.53% in the recent trading with $2.29 being its most recent. The current price level -31.33% lower than the highest price of $3.34 marked by the stock while trading over the past 52-weeks, whereas it is 227.14% higher than the lowest price of $0.70 the company dropped to over past 52-weeks. The latest news story on ESPR appeared in (Business Wire) under the title “U.S. FDA Approves Broad New Labels for Esperion’s NEXLETOL and NEXLIZET to Prevent Heart Attacks and Cardiovascular Procedures in Both Primary and Secondary Prevention Patients, Regardless of Statin Use”.
Squeezing the time span to 30 day period shows us the stock is currently trading -24.42% below one month high and is +19.27% above of the lowest during that time. Looking into the simple moving average, Esperion Therapeutics Inc. (ESPR)’s stock stands at a SMA-50 of $2.38 while that of 5-day is reading $2.14.
Daily rise and fall of price influence many of the traders, and in order to overcome the fluctuating effect of that and to watch the stock closely, traders focus more on stock’s 200-day moving average. At various points in trading activity, investors are more likely to be making use of that measure as a strong indicator in figuring out their support and resistance levels, and ESPR’s SMA-200 as of now is $1.67.
Do analysts rate it as a buy, sell or hold?
Irrespective of recent performance, what’s important is what the future holds. In uncertain economic times, a clear picture is difficult to get. Analysts generally have a good understanding of the market works, which gives them a leg up in making predictions. Analyst ratings are often compiled into a single score from 1 to 5. The score of 1 signifies buy or strong buy, the score of 2 signifies outperform, the score of 3 means hold, and the score of 4 indicates underperform. The simple numeric range of brokerage firm referenced at the scale of 1 to 5 reads a current average recommendation of 1.57 for the stock.
Esperion Therapeutics Inc. Earnings – What Happened With ESPR
Coming around sales and income figures on ESPR Stock Income Statement, public trading companies under normal circumstances post earnings and revenues near to average estimates by the Wall Street analysts, but those could came either above or below estimates and known as surprise factor. Esperion Therapeutics Inc. (ESPR) last released financial results for the quarter that ended 12/30/2023, posting a surprise factor of -4.20% for net revenue.
ESPR – Esperion Therapeutics Inc. Stock Earnings Estimates
The perspective of Esperion Therapeutics Inc. (NASDAQ:ESPR)’s current quarter earnings identifies that analysts are in consensus over the estimate of -0.48 for stock’s EPS in the current quarter. 7 analysts covering the stock at Wall Street were agreed upon that EPS consensus. Company’s EPS for the last quarter was -0.5.
Investors get the exact data about the key information of institutional ownership in a listed company through its 13F filings at the Stock Exchange Commission (SEC). The total number of common shares currently owned by the public is 170.42 million. ESPR does have institutional investors; and they hold 48.10% of the stock.
Esperion Therapeutics Inc. – Insider Activity and Holdings
As on Dec 30, 2023, Wasatch Advisors LP was the top most holder in Esperion Therapeutics Inc. (NASDAQ:ESPR) with an ownership of 8.89 million shares of the company or 4.80% of the stake worth $20.36 million. The filing also reveals Two Seas Capital Lp as the second largest holder in the company with a control over 4.15% of the outstanding shares. Its stake is worth $17.6 million for having 7.69 million shares in hand.
Vanguard Group Inc also came holding a key position in the company during the recent quarter and it now holds 2.78% of the outstanding shares. With this there are now 161 institutions which have possession in ESPR’s shares.
Analyst ratings are often compiled into a single score from 1 to 5. The score of 1 signifies buy or strong buy, the score of 2 signifies outperform, the score of 3 means hold, and the score of 4 indicates underperform. The simple numeric range of brokerage firm referenced at the scale of 1 to 5 reads a current average recommendation of 1.57 for the stock.
Technical Analysis of Esperion Therapeutics Inc. (NASDAQ:ESPR) stock
To comprehend better with the trade moves and investors’ behavior, exploring the short, medium and long term technical indicators along with average volume of a stock is an effective way to make use of. When looking into those indicators for Esperion Therapeutics Inc. (ESPR), we notice that the stock’s 20-day average volume is at 4,630,720 shares. Medium term indicators at an average of 50% are spotting the stock at Buy with its 50-day average volume of 5,655,316 shares. And to end, ESPR’s 100-day average volume is 5,342,087 shares with 100% of the long-term indicators pointing towards Buy for the stock.
